Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Zilebesiran: KARDIA-3 Study

Standard response letter on zilebesiran and the KARDIA-3 study, an ongoing phase 2 study evaluating the efficacy and safety of zilebesiran in patients with high CV risk and hypertension that is not adequately controlled with at least 2 standard-of-care antihypertensives.

Clinical Outcomes in Patients with Acute Hepatic Porphyria Treated with Givosiran Who Stopped Hemin Prophylaxis at Study Entry: Post hoc Analyses from the Phase 3 ENVISION Study Through Month 36

Zilebesiran: Phase 1 Study Overview

Standard response letter on the phase 1 study of zilebesiran, a study evaluating the safety, PK , PD, as well as exploratory antihypertensive efficacy of zilebesiran in patients with hypertension.

INTERACTIVE INFOGRAPHIC: Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6-months of givosiran treatment: a subgroup analysis of the phase 3 ENVISION study

Vutrisiran: Vitamin A Levels

Standard response letter on vutrisiran and vitamin A levels, including information on supplementation.

Patisiran: Management of Infusion-Related Reactions

Standard response letter on the management of infusion-related reactions in patisiran clinical studies.

Vutrisiran: Pharmacokinetic and Pharmacodynamic Properties

Standard Response Letter on vutrisiran and its pharmacokinetic and pharmacodynamic properties.

Patisiran: Preparation and Administration

Standard response letter on the preparation and administration of patisiran.

Vutrisiran: Transitioning from Antisense Oligonucleotide

Standard response letter on transitioning from an antisense oligonucleotide to vutrisiran.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.